Dr. Jiaoti Huang’s laboratory has been studying the molecular mechanisms by which prostate cancer becomes insensitive to hormonal therapy and progresses to castration resistant tumors. His lab is actively engaged in drug discovery and in developing tumor models that can be used for the development of tools used in diagnosis, imaging, prevention and therapy of prostate cancer.
Selected Cancer-Related Publications:
Ding B, Sun Y, Huang J. Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. J Biol Chem. 2012 Apr 27;287(18):14621-30. Epub 2012 Mar 12
Chen H, Sun Y, Wu C, Magyar C, Li X, Cheng L, Yao JL, Shen S, Osunkoya AO, Liang C, Huang J, Magyar CE. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer. 2012 Jun;19(3):321-31.
Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta S, Thor RK, Damoiseaux R, Liang C, Huang J. Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells. Mol Cancer Ther. 2012 Jun;11(6):1320-31. Epub 2012 Apr 5
Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011 Nov;71(15):1668-79. Epub 2011 Mar 22
Huang J, Witte ON. A seminal finding for prostate cancer? N Engl J Med. 2010 Jan 14;362(2):175-6.